275
Participants
Start Date
January 10, 2020
Primary Completion Date
October 6, 2023
Study Completion Date
October 6, 2023
NNC0365-3769 (Mim8)
Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
Placebo (Mim8)
Mim8 placebo administered subcutaneously (s.c., under the skin)
UMHAT Tsaritsa Yoanna-ISUL EAD, Sofia
Charlotte Maxeke Johannesburg Academic Hospital, Parktown, Johannesburg
Universitätsklinik für Hämatologie, Bern
Universitätsklinik für Innere Medizin V, Innsbruck
Charité - Campus Charité Mitte - Charité Research Organisation GmbH, Berlin
Istituto di Medicina Int. A. Bianchi Bonomi Univ. Milano, Milan
Trakya University, Edirne
Hospital Universitario La Paz, Madrid
Hospital Regional Universitario de Málaga, Málaga
Ege Universitesi Tip Fakultesi, Izmir
Dayton Children Hemostati Ctr, Dayton
University Of Michigan, Ann Arbor
University of Iowa_Iowa City, Iowa City
Rush University Med. Cntr, Chicago
Children's Hospital Los Angeles - Endocrinology, Los Angeles
Universitätsklinik für Innere Medizin V, Innsbruck
Policlinico Umberto I Sezione Ematologia, Roma
Nagoya University Hospital_Blood Transfusion, Aichi
Uniwersytecki Szpital Kliniczny W Poznaniu, Poznan
Instytut Hematologii i Transfuzjologii, Warsaw
Hacettepe University Medical Faculty, Ankara
Royal Free Haemophilia Comprehensive Care Centre, London
Lead Sponsor
Novo Nordisk A/S
INDUSTRY